The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
The Receptor-associated Protein (RAP) As A Molecular Chaperone For The Amyloid Protein (Abeta) Of Alzheimers Disease
Funder
National Health and Medical Research Council
Funding Amount
$402,403.00
Summary
Our research will examine the role of a protein known as the receptor-associated protein (RAP) in Alzheimer's disease. We will determine whether the protein contributes to the progression of Alzheimer's disease and we will examine the possiblity that that RAP may be used as a drug to treat the disease. The project could potentially have direct benefit for patients by leading to an effective treatment for dementia associated with Alzheimer's disease.
Extracellular Matrix, Cell-surface Receptors And Alzheimer's Disease: A Novel Glycoform Of Acetylcholinesterase
Funder
National Health and Medical Research Council
Funding Amount
$265,074.00
Summary
Alzheimer's disease is the leading cause of dementia in the elderly, affecting approximately 5-10% of the population over the age of 65. With an increasingly ageing population, Alzheimer's disease will be a major health problem in the next century unless effective treatments (probably in combination with early diagnosis) are found. We have identified a novel form of a protein acetylcholinesterase (AChE-AD), which is present in high levels in the brains of patients with Alzheimer's disease. Our w ....Alzheimer's disease is the leading cause of dementia in the elderly, affecting approximately 5-10% of the population over the age of 65. With an increasingly ageing population, Alzheimer's disease will be a major health problem in the next century unless effective treatments (probably in combination with early diagnosis) are found. We have identified a novel form of a protein acetylcholinesterase (AChE-AD), which is present in high levels in the brains of patients with Alzheimer's disease. Our work has shown that the accumulation of another protein in the brains of Alzheimer patients, known as the amyloid protein, is the cause of the increase in AChE-AD. This finding is important for two reasons: 1) Identification of the mechanism by which the amyloid protein causes an increase in AChE-AD will tell us about some of the basic causes of Alzheimer's disease. 2) AChE-AD may be a useful diagnostic marker of Alzheimer's disease. At present, diagnosis is performed by clinical examination. This is a time consuming and inaccurate process. A biochemical diagnostic marker will provide an objective criterion with which to diagnose Alzheimer's disease. Therefore, our research is aimed at: Aim 1: Evaluating AChE-AD as a diagnostic marker. Aim 2: Developing tools with which we can more easily measure AChE-AD. Aim 3: Understanding the basic biochemical mechanisms which cause the increase in AChE-AD in the brains of patients. Aim 4: Examining whether AChE-AD may contribute to the cause of Alzheimer's disease.Read moreRead less
The Role Of Copper In Ubiquitin-dependent Protein Degradation In Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$588,622.00
Summary
Ubiquitin’s are small proteins that tag other proteins in a process known as “Ubiquitination”. Often this is to target them for degradation once they are no longer needed i.e. to take out the rubbish. This process is disrupted in Alzheimer’s disease (AD), which may contribute to the disease. This project aims to find out if copper, an essential metal for life, is required for this process. Drugs that are designed to deliver copper to brain cells have been effective in small AD clinical trials.
Cellular Pathogenesis Of Neurodegenerative Disorders
Funder
National Health and Medical Research Council
Funding Amount
$124,530.00
Summary
Alzheimer's disease is the most common neurodegenerative disease of the ageing population and is associated with toxicity of the Abeta peptide. Prion diseases (eg CJD in humans) are infectious neurodegenerative disorders caused by misfolding of the prion protein. This proposal aims to bring together similar features of these diseases using novel cell and animal based studies to develop better diagnostics and greater understanding of the molecular basis of these disorders with a view to developin ....Alzheimer's disease is the most common neurodegenerative disease of the ageing population and is associated with toxicity of the Abeta peptide. Prion diseases (eg CJD in humans) are infectious neurodegenerative disorders caused by misfolding of the prion protein. This proposal aims to bring together similar features of these diseases using novel cell and animal based studies to develop better diagnostics and greater understanding of the molecular basis of these disorders with a view to developing interventional therapies.Read moreRead less
Cholinergic Abnormalities In Alzheimer's Disease: Identification Of Novel Therapeutic Targets
Funder
National Health and Medical Research Council
Funding Amount
$478,500.00
Summary
The aim of this project is to develop new drugs for the treatment of Alzheimer's disease. Alzheimer's disease is a disease of ageing commonly associated with memory loss. The disease is caused by the build up of amyloid protein in the brain. However, it is not known how amyloid protein causes degeneration of normal brain function. Our previous studies have shown that amyloid protein targets two components which are important for normal brain function. These components are 1) acetylcholinesterase ....The aim of this project is to develop new drugs for the treatment of Alzheimer's disease. Alzheimer's disease is a disease of ageing commonly associated with memory loss. The disease is caused by the build up of amyloid protein in the brain. However, it is not known how amyloid protein causes degeneration of normal brain function. Our previous studies have shown that amyloid protein targets two components which are important for normal brain function. These components are 1) acetylcholinesterase and 2) nicotinic receptors, which are known to be important for memory. The aim of this application is to identify the mechanisms by which amyloid protein targets acetylcholinesterase and nicotinic receptors and to design inhibitors of this interaction which may ultimately provide a platform for future drug development.Read moreRead less